South San Francisco personalized medicine/diagnostics startup Nodality has signed a multi-year collaborative deal with Belgium's UCB Pharma that will initially focus on possible companion diagnostics for drugs to treat immunology disorders. Neither side disclosed financial terms or deal details. In fact, the deal announcement is frustratingly vague; it states both sides will focus on "development of several UCB compounds," and the Belgian company will gain the option to have Nodality develop companion diagnostics for its drugs. Terms call for Nodality to gain an initial payment up front, money for R&D and additional cash once the companies meet development, regulatory and commercial milestones. Nodality's Single Cell Network Profiling technology is meant to help target disease variability in individual patients and aid in determining that best treatment pathway. Nodality, which launched in 2007, employs 42 people and has raised more than $50 million in venture funding to date. Release